When to move up or stay on a hCG dose
Reviewed 15 sourcesPublished by PepVault
What the FDA labels and studies tie an hCG dose change to (blood testosterone first, then sperm), how long each takes to show, and who makes the call.

- Last reviewed
- Sources
- 15
- Questions
- 7
- Compounds
- 1
The short answer
No hCG label gives men on TRT a step-up. The labels that do adjust hCG tie the change to blood testosterone: Follistim's allows 1,500 IU twice weekly to become 3,000 IU if testosterone is still low after 8 weeks, and Gonal-f's says the dose may need raising until it is normal. Studies also tracked semen and estradiol. The change is your prescriber's decision.
Evidence: hCG is an FDA-approved biologic; the step-up rules come from FDA labels and their open-label trials, the dose-response data from small randomized studies in healthy men, and the TRT and fertility outcomes from case series and records studies.

What do the labels say about raising an hCG dose?
The most concrete hCG step-up rules are not in the hCG labels at all. They sit in the labels of two FSH drugs, Follistim AQ and Gonal-f, because both are used with hCG to start sperm production in men with hypogonadotropic hypogonadism (low testosterone because the pituitary sends too little LH, the hormone hCG stands in for)34. Both tie the hCG dose to one number: blood testosterone.
| Label | Starting hCG | When it changes | What decides it |
|---|---|---|---|
| Follistim AQ (Organon)3 | 1,500 IU twice weekly, alone first | If testosterone has not normalized after 8 weeks, it can go to 3,000 IU twice weekly | Blood testosterone |
| Gonal-f (EMD Serono)4 | 1,000 to 2,250 USP units two to three times a week, alone first | "May also need to be increased" while testosterone is brought into range, which may take 3 to 6 months | Blood testosterone |
| Pregnyl and Novarel (hCG)12 | 500 to 1,000 USP units three times a week for 3 weeks, then twice a week for 3 weeks; or 4,000 units three times weekly | The 4,000-unit course may be reduced to 2,000 units three times weekly after 6 to 9 months, for 3 more months | Not stated; the labels say the regimen depends on the indication, age, weight and the physician's preference |
Two things stand out. The hCG labels' only change for men is a step down, not up12. And once testosterone is normal, the FSH labels hold the hCG dose where it is: Follistim's says FSH is added "with the same hCG dose used to normalize testosterone levels", and Gonal-f's names 1,000 units three times a week "or the dose required to maintain serum testosterone levels within the normal range"34. In Follistim's own trial, men who had needed 3,000 IU stayed on 3,000 IU for the whole 48-week treatment phase3.
Where the labels do move a dose for sperm, it is the FSH partner that moves. Gonal-f's says that if azoospermia (no sperm in the semen) persists, its own dose rises, to at most 300 IU three times a week, for up to 18 months4. Using hCG beside TRT is not among the labels' indications, so no label rule covers it12.

Which number decides whether the dose changes?
Three measures run through the labels and studies, and each answers a different question.
| Measure | What it tells you | How the sources used it |
|---|---|---|
| Blood testosterone | Whether the testes are answering the hCG signal | The labels' trigger for a higher hCG dose34; in a 223-man study, doses were adjusted to testosterone, drawn 48 hours after a shot9 |
| Semen analysis (sperm count) | Whether sperm production is starting or holding | Doses adjusted to "sperm output" in the same study9; the Gonal-f label raises FSH, not hCG, when sperm stay absent4 |
| Estradiol | How much of the extra testosterone is turning into estrogen | Measured in the studies, not a dose trigger in any label: it rose about 150% on 5,000 IU twice weekly11 and did not change significantly on 500 IU every other day beside TRT10 |
Behind the testosterone rule sits a clean dose-response. In a 3-week randomized study of 29 healthy men on 200 mg of testosterone enanthate a week, testosterone inside the testes fell 94% with placebo; with hCG every other day it ended 25% below baseline at 125 IU, 7% below at 250 IU and 26% above at 500 IU, rising in a straight line with the dose5. A follow-up in 37 men whose own LH had been switched off by a drug found the same rise at even lower doses over 10 days: from 77 nmol/L with no hCG to 923 nmol/L at 125 IU every other day6.
Those inside-the-testes numbers came from fine-needle samples of testicular fluid, a research test. In practice, blood testosterone and the semen analysis are what a prescriber sees.
PepVault's bloodwork log records total and free testosterone, LH, FSH and estradiol, so each draw sits beside the one before it. Log it in PepVault
Is one bigger shot better than more small ones?
Not in the studies that tested it. Testes answer a large single shot by briefly turning down their own response, which researchers call desensitization. In seven healthy men, one 1,500 IU shot doubled testosterone at 48 hours, then let it fall to 0.7 times baseline by day 78. The same 1,500 IU split into five daily 300 IU shots also doubled testosterone, kept it up, and gave almost twice the total testosterone exposure (2,844 vs 1,647 units of area under the curve)8.
Estradiol behaved differently on the two schedules. After the single shot it peaked at 4.4 times baseline at 24 hours; on the divided doses that early peak was absent8. In normal men given single shots of up to 6,000 IU, estradiol rose with the dose and peaked at 24 hours, while testosterone peaked at 48 hours and, at 6,000 IU, was still raised 6 days later7.
hCG itself stays in the blood for days (its half-life, pepvault.app/glossary/half-life, is the time for the level to halve): in 18 women whose own gonadotropins were switched off, one shot peaked about 20 hours later and had a half-life of 32 to 33 hours, the same into muscle or under the skin13. That fits the two- and three-times-a-week schedules in the labels and studies134, and the curve below shows how a split or merged dose changes it.
Try it
How HCG builds up
An estimate from a half-life of about 33 hours, one dose a day for four weeks. The shape of the level, not a measurement.
How long before a dose change shows?
Testosterone moves in days; sperm take months. The waiting periods in the sources line up like this:
| What is measured | How long the sources waited or saw | Source |
|---|---|---|
| Testosterone after one shot | Peak at about 48 hours | 78 |
| Testosterone on a new starting dose | 8 weeks before the label's step-up | Follistim label3 |
| Testosterone into the normal range | 3 to 6 months of hCG alone | Gonal-f label4 |
| Sperm returning after testosterone use | 4.6 months on average, on 3,000 IU every other day plus other drugs | 49-man case series12 |
| Sperm reaching 1 to 1.5 million/mL with added FSH | Median 165 days (Follistim); median 9 to 12.4 months (Gonal-f trials) | 34 |
| Sperm appearing, from no puberty | Median 15 months on hCG plus hMG | 223-man study9 |
| Sperm count plateau in teenagers | About 30 months of hCG, given until growth and counts stopped rising | 60 patients aged 14 to 2214 |
The Follistim label puts the sperm side plainly: the combined treatment should run at least 3 to 4 months before any improvement in sperm production can be expected3.
Does hCG increase LH?
No. hCG acts like LH at the testes, so the brain reads the extra testosterone and sends less of its own. In a placebo-controlled trial in 40 men over 60, 5,000 IU twice weekly raised testosterone and estradiol about 150%, while LH and FSH fell and testis volume shrank by about 5 mL over 3 months11. LH and FSH also fell in men on hCG with TRT in a records study of 6,999 men15.
That makes an LH result a poor guide to an hCG dose. Both hCG labels add that hCG can cross-react in gonadotropin tests, especially LH, and ask that the lab be told whenever gonadotropin levels are requested12.
What does staying on the same dose look like?
A clinic's records of 26 men on TRT plus a fixed 500 IU every other day, into muscle, show what holding a dose did (mean follow-up 6.2 months). Testosterone rose from 207.2 to 1,055.5 ng/dL, estradiol did not change significantly, semen measures did not shift over more than a year, no man lost his sperm, and 9 contributed to a pregnancy10.
Commonly reported: men on hCG beside TRT describe the testes regaining size and fullness over the first weeks, and puffiness or tender nipples as the sign that sends them for an estradiol check.
The labels list fluid retention at high doses, from the extra testosterone hCG drives, and occasional breast enlargement (gynecomastia) in men1. In the trial in older men, 3 had nipple tenderness that did not progress to gynecomastia11. The side-effects page at pepvault.app/peptides/hcg/side-effects lists the rest, and two of the studies above have their own pages: pepvault.app/research/hcg-hsieh-2013 and pepvault.app/research/hcg-wenker-2015.
What do you bring to the prescriber's review?
The decision to move up, stay or come down belongs to your prescriber, read against your own results. What you can do is make those results easy to read.
- Ask your prescriber when to draw testosterone after a shot; the 223-man study drew it 48 hours after one9.
- Tell the lab you are on hCG if LH or FSH is on the order, as both labels ask12.
- Keep each dose and the date it changed, so every result can be matched to the dose that produced it.
- If fertility is the goal, ask whether a semen analysis belongs in the plan, since testosterone alone does not show sperm production49.
- Bring the results and the dose record to the review, and let the prescriber make the call.
PepVault logs each shot as you take it, and its doctor's report puts each compound's dose and how many doses you logged beside your bloodwork, before and after, ready for that appointment. Log it in PepVault
When to get help Hives, swelling of the face or throat, or trouble breathing after a shot is a reason to get help at once, since the labels list allergic reactions, including anaphylaxis1.
Sources
- Pregnyl (chorionic gonadotropin for injection) prescribing information, Organon. DailyMed, published Dec 4, 2025. dailymed.nlm.nih.gov
- Novarel (chorionic gonadotropin for injection) prescribing information, Ferring. DailyMed, published Sep 25, 2025. dailymed.nlm.nih.gov
- Follistim AQ Cartridge (follitropin beta injection) prescribing information, Organon. DailyMed, published May 28, 2026. Sections 2.4 and 14.3. dailymed.nlm.nih.gov
- Gonal-f (follitropin alfa for injection) prescribing information, EMD Serono. DailyMed, published Sep 5, 2025. Sections 2.5 and 14.3. dailymed.nlm.nih.gov
- Coviello AD et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005. PubMed 15713727
- Roth MY et al. Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab. 2010. PubMed 20484472
- Padrón RS et al. Prolonged biphasic response of plasma testosterone to single intramuscular injections of human chorionic gonadotropin. J Clin Endocrinol Metab. 1980. PubMed 7372789
- Smals AG et al. Differential effect of single high dose and divided small dose administration of human chorionic gonadotropin on Leydig cell steroidogenic desensitization. J Clin Endocrinol Metab. 1984. PubMed 6693540
- Liu Z et al. Efficacy and outcome predictors of gonadotropin treatment for male congenital hypogonadotropic hypogonadism: a retrospective study of 223 patients. Medicine (Baltimore). 2016. PubMed 26945370
- Hsieh TC et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013. PubMed 23260550
- Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab. 2002. PubMed 12107212
- Wenker EP et al. The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. J Sex Med. 2015. PubMed 25904023
- Mannaerts BM, Geurts TB, Odink J. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod. 1998. PubMed 9688371
- Rohayem J et al. Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? A multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. Clin Endocrinol (Oxf). 2017. PubMed 27467188
- Clift AK, Johnson H, Huang DR, Ramasamy R. Pituitary axis impacts and effectiveness of clomiphene and human chorionic gonadotropin in treating hypogonadism: cohort study. World J Mens Health. 2026. PubMed 42402873
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.